ImmunoPrecise Antibodies Ltd. (IPA)

ImmunoPrecise Antibodies Revenue

ImmunoPrecise Antibodies had revenue of 6.15M CAD in the quarter ending January 31, 2025, a decrease of -1.13%. This brings the company's revenue in the last twelve months to 24.00M, up 1.34% year-over-year. In the fiscal year ending April 30, 2024, ImmunoPrecise Antibodies had annual revenue of 24.52M with 18.65% growth.

• Revenue (ttm): 24.00M CAD
• Revenue Growth: +1.34%
• P/S Ratio: 1.75
• Revenue / Employee: 237,604 CAD
• Employees: 101
• Market Cap: 50.80M USD

Revenue Chart

* This company reports financials in CAD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Apr 30, 2024	24.52M	3.85M	18.65%
Apr 30, 2023	20.67M	1.30M	6.72%
Apr 30, 2022	19.36M	1.45M	8.11%
Apr 30, 2021	17.91M	3.85M	27.42%
Apr 30, 2020	14.06M	3.13M	28.66%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.